Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.
April 2015Barrett AJ, et al. Blood — Although tyrosine kinase inhibitors (TKIs) have largely replaced hematopoietic cell transplantation (HCT) as first-line treatment for chronic myelogenous leukemia (CML), the authors of this review note that HCT remains a curative option for accelerated/blastic-phase CML and selected chronic-phase CML.
September 2014Adekola K, et al. Bone Marrow Transplant — This review of allogeneic HCT in patients with chronic myelogenous leukemia (CML), myelofibrosis, and chronic myelomonocytic leukemia includes discussion of how the use of tyrosine kinase inhibitors (TKIs) affects clinicians’ decision-making on the timing to pursue transplantation in patients with these diseases.
Hahn T, et al. J Clin Oncol - Survival for patients undergoing allogeneic hematopoietic cell transplantation (HCT) has significantly improved over time, according to a study of 38,060 patients with hematologic malignancies transplanted between 1994 and 2005 and reported to CIBMTR (Center for International Blood and Marrow Transplant Research).
Storb R, et al. J Clin Oncol - A study of a minimal-intensity pre-transplant conditioning regimen consisting of low-dose total body irradiation with or without fludarabine has shown that it can induce strong graft-versus-tumor (GVT) effects leading to lasting remissions in 45% to 75% of patients.